化学
乙酰胺
止痛药
磺酰
体内
最大值
药代动力学
IC50型
生物利用度
TRPV1型
药理学
体外
生物化学
有机化学
受体
瞬时受体电位通道
生物技术
生物
烷基
医学
作者
Wenli Chen,Qinlong Xu,Xiaodong Ma,Jiajia Mo,Gaofeng Lin,Guangwei He,Zhaoxing Chu,Jiaming Li
标识
DOI:10.1016/j.bmcl.2022.129101
摘要
In this study, a series of structurally novel N-(benzene sulfonyl) acetamide derivatives were designed, synthesized, and biologically evaluated as COX-2/5-LOX/TRPV1 multitarget inhibitors for anti-inflammatory and analgesic therapy. Among them, 9a and 9b displayed favorable COX-2 (9a IC50 = 0.011 μM, 9b IC50 = 0.023 μM), 5-LOX (9a IC50 = 0.046 μM, 9b IC50 = 0.31 μM) and TRPV1 (9a IC50 = 0.008 μM, 9b IC50 = 0.14 μM) inhibitory activities. The pharmacokinetic (PK) study of 9a in SD rats at the dosage of 10 mg/kg demonstrated a high oral exposure, an acceptable clearance and a favorable bioavailability (Cmax = 5807.18 ± 2657.83 ng/mL, CL = 3.24 ± 1.47 mL/min/kg, F = 96.8 %). Further in vivo efficacy studies illustrated that 9a was capable of ameliorating formalin-induced pain and inhibiting capsaicin-induced ear edema.
科研通智能强力驱动
Strongly Powered by AbleSci AI